In the following video, Motley Fool health-care analyst David Williamson highlights one pharmaceutical company that has no interest in organic growth. Valeant Pharmaceuticals (BHC 0.70%) is continuing its growth-through-acquisition strategy with the purchase of Obagi Medical Products (NASDAQ: OMPI), its 21st acquisition since 2011, for $344 million. David tells investors why this is a win for both parties, and how they should think of the investing thesis behind Valeant.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.